Cardiovascular risk factors increase the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms ...

INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.